Edition:
United Kingdom

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

8.38USD
20 Apr 2018
Change (% chg)

$0.05 (+0.60%)
Prev Close
$8.33
Open
$8.29
Day's High
$8.49
Day's Low
$8.29
Volume
139,754
Avg. Vol
210,319
52-wk High
$17.96
52-wk Low
$7.82

Select another date:

Thu, Mar 29 2018

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:

BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes

* LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES

BRIEF-Lexicon Pharmaceuticals Q4 Loss Per Share $0.27

* LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BRIEF-Biopharma Credit Says Enetered Into Term Loan Agreement For Up To US$200 Mln With Lexicon Pharmaceuticals

* BIOPHARMA CREDIT PLC SAYS ENETERED INTO A DEFINITIVE TERM LOAN AGREEMENT FOR UP TO US$200 MILLION WITH LEXICON PHARMACEUTICALS, INC. Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Lexicon Pharmaceuticals Secures Up To $200 Million Non-Dilutive Term Loan Financing

* LEXICON PHARMACEUTICALS SECURES UP TO $200 MILLION NON-DILUTIVE TERM LOAN FINANCING

BRIEF-Lexicon Pharmaceuticals reports Q3 loss per share $0.29

* Lexicon Pharmaceuticals reports third quarter 2017 financial results and provides a business update

Select another date: